Main menu

NEW YORK (GenomeWeb News) – Abbott reported today that its molecular diagnostics sales grew 4 percent year over year for its fourth quarter ended Dec. 31, 2012.

The diagnostics, medical devices, and pharmaceuticals giant reported molecular diagnostics sales of $131 million for the quarter, up from $126 million for the fourth quarter of 2011. Its core laboratory diagnostics revenues for the quarter were also up 4 percent to $908 million, while its point-of-care diagnostics sales climbed 15 percent to $90 million.

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.